NASDAQ:RNAZ
TransCode Therapeutics
- Stock
Last Close
0.88
17/05 20:00
Market Cap
7.02M
Beta: -
Volume Today
3.90M
Avg: 1.67M
PE Ratio
−0.06
PFCF: −0.23
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 277.17K - | 277.17K 0% | ||||
average payables | 2.17M - | 2.17M 0% | ||||
average receivables | 180.11K - | 180.11K 0% | ||||
book value per share | -4.33 - | -10.68 146.62% | 48.43 553.56% | 0.25 99.48% | 9.17 3,570.59% | |
capex per share | -0.60 - | -0.01 98.71% | ||||
capex to depreciation | -6 - | -1.02 82.94% | ||||
capex to operating cash flow | 0.05 - | 0.01 86.77% | ||||
capex to revenue | ||||||
cash per share | 0.80 - | 2.59 225.20% | 49.43 1,805.48% | 0.38 99.23% | 15.46 3,938.31% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 4.54 - | 1.98 56.43% | 0.09 - | |||
debt to equity | -0.84 - | -0.61 26.77% | 0.27 - | |||
dividend yield | ||||||
earnings yield | -0.04 - | -0.11 187.77% | -0.32 202.30% | -0.20 37.97% | -15.72 7,717.17% | |
enterprise value | 21.23M - | 26.79M 26.21% | 575.88K 97.85% | 169.71M 29,369.08% | -1.14B 770.21% | |
enterprise value over ebitda | -46.47 - | -36.88 20.63% | -0.10 99.73% | -9.72 9,735.76% | 0.06 100.63% | |
ev to operating cash flow | -41.75 - | -54.35 30.19% | -0.11 99.80% | -10.77 9,746.80% | 0.06 100.58% | |
ev to sales | ||||||
free cash flow per share | -1.98 - | -1.54 22.15% | -13.11 748.58% | -1.22 90.67% | -100.97 8,160.09% | |
free cash flow yield | -0.02 - | -0.02 22.15% | -0.26 1,236.35% | -0.09 64.80% | -15.32 16,771.13% | |
graham net net | -4.33 - | -11.39 163.07% | 43.42 481.17% | 0.09 99.79% | -4.25 4,823.33% | |
graham number | 17.04 - | 45.40 166.40% | 133.97 195.07% | 3.90 97.09% | 146.18 3,648.11% | |
income quality | 0.84 - | 0.21 74.89% | 0.77 265.93% | 0.90 16.60% | 0.97 8.60% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -2.91 - | -1.84 36.73% | -64.70 3,413.51% | -1.06 98.36% | 331.78 31,321.15% | |
interest debt per share | 4.23 - | 7.77 83.68% | 0.23 97.10% | 1.35 499.80% | 2.20 62.89% | |
inventory turnover | ||||||
invested capital | -0.84 - | -0.61 26.77% | 0.27 - | |||
market cap | 20.50M - | 25.53M 24.53% | 21.40M 16.18% | 174.67M 716.17% | 1.18B 575.35% | |
net current asset value | -1.11M - | -3.63M 227.31% | 20.20M 656.06% | 3.03M 84.99% | 926.56M 30,458.11% | |
net debt to ebitda | -1.58 - | -1.73 9.42% | 3.57 306.19% | 0.28 92.04% | 0.12 56.08% | |
net income per share | -2.98 - | -8.58 187.77% | -16.47 91.96% | -2.71 83.56% | -103.61 3,727.28% | |
operating cash flow per share | -1.98 - | -1.54 22.15% | -12.50 709.42% | -1.21 90.28% | -100.97 8,212.97% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -3.74 - | -2.59 30.57% | -0.30 88.34% | -4.63 1,430.56% | -3.59 22.51% | |
revenue per share | ||||||
roe | 0.69 - | 0.80 16.69% | -0.34 142.32% | -10.84 3,087.85% | -11.30 4.27% | |
roic | 3.16 - | 0.64 79.67% | -0.31 147.58% | -11.52 3,668.90% | -7.30 36.66% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | -4.33 - | -10.68 146.62% | 48.43 553.56% | 0.25 99.48% | 9.17 3,570.59% | |
stock based compensation to revenue | ||||||
tangible asset value | -1.11M - | -3.41M 207.11% | 20.40M 698.68% | 3.24M 84.12% | 1.64B 50,531.53% | |
tangible book value per share | -4.33 - | -10.68 146.62% | 48.43 553.56% | 0.25 99.48% | 9.17 3,570.59% | |
working capital | 141.53K - | 426.35K 201.25% | 20.20M 4,637.41% | 3.03M 84.99% | 964.85M 31,720.96% |
All numbers in USD (except ratios and percentages)